ProCE Banner Activity

The Wait Is On: Anticipating the Uses of Long-Acting ART and PrEP in Africa

Clinical Thought

As most countries in Africa await approval and implementation guidance for several long-acting HIV treatment and prevention options, it is important for healthcare professionals and policymakers to stay abreast of continually emerging data on the use of these strategies. Four key reports from IAS 2023 provide helpful new insights.

Released: September 06, 2023

Share

Faculty

Linda-Gail Bekker

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD

CEO, Desmond Tutu Health Foundation
Director, Desmond Tutu HIV Centre
Professor of Medicine
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa

Provided by

 Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

ViiV Healthcare

Partners

IAS 2023

ProCE Banner

Faculty Disclosure

Primary Author

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD

CEO, Desmond Tutu Health Foundation
Director, Desmond Tutu HIV Centre
Professor of Medicine
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa

Linda Gail-Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD: consultant/advisor/speaker: Gilead, Merck, ViiV.